On LinkedIn, SVP and President of Abbott Vascular, Julie Tyler, posted that the Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through (TPT) payment status for Esprit BTK.

TPT, a three-year program, ensures that Medicare beneficiaries can benefit from a technology without cost barriers. Now, Esprit BTK has support from both inpatient new technology add-on payment (NTAP) and outpatient TPT. It provides a clearer path to adopt the therapy, Tyler wrote.